Answers are grounded in this paper and cite their sources.
Recent advances towards the cure for hepatitis C virus (HCV) infection have largely been successful, more so with minimal or no side effects of the anti-HCV drugs and not requiring combination therapies. In patients co-infected with human immunodeficiency virus (HIV) the chances of reoccurrence of HCV co-infection is more likely clinically either due to contaminated blood transfusions, or the immuno-suppressive nature of HIV. Hence the curative action of drugs against HCV infection is unrelated to any concomitant reduction of co-infection unrelated HIV replication. Thus HIV infected patients are always at risk to re-contract HCV infection. However any progress of the even in a transiently cured HCV infected patients are much less likely to progress into the slow developing hepato cellular carcinoma (HCC) and associated liver cirrhosis leading to HCV related death. Whereas the protease inhibitors of HCV are efficacious for a cure those of HIV seem to be restricted to its containment but not elimination from the human circulatory system.
No takes yet. Share an insight, caveat, or question.
Prasad S Koka (2015) studied this question.
Synapse has enriched 4 related papers. Consider them for comparative context: